The resultant therapeutic candidate sBCMA-Fc V3 showed superior antitumor activities for both APRIL-driven MM and BAFF-driven DLBCL, with a desirable safety profile. The gene discussed is TNFSF13B; the disease is Miyoshi myopathy.